Episode 77: CAR T-cell and Cytokine Release Syndrome

Chimeric antigen receptor (CAR) T-cell therapy represents a sophisticated immunomodulation technique where genetically modified T-cells are engineered to target malignancies like leukemia and multiple myeloma. While effective, this therapy frequently triggers Cytokine Release Syndrome (CRS), a systemic inflammatory response characterized by fever and multi-organ dysfunction. Clinical presentation ranges from mild flu-like symptoms to life-threatening hypotension and hypoxia, often mimicking septic shock or tumor lysis syndrome. Diagnosis relies on a grading system (Grades 1-4) that dictates management strategies, including the use of the IL-6 antagonist tocilizumab and corticosteroids for severe cases. Emergency department evaluation requires a high index of suspicion, focusing on the timing of the infusion—typically within one to two days of symptom onset—and comprehensive laboratory testing to identify end-organ injury. Stabilization involves aggressive fluid resuscitation, vasopressors, and broad-spectrum antibiotics to address potential concomitant sepsis.